Girerd X, Laurent S, Pannier B, Asmar R, Safar M
Department of Internal Medicine, Broussais Hospital, France.
Am Heart J. 1991 Oct;122(4 Pt 2):1210-4. doi: 10.1016/0002-8703(91)90941-a.
Reduced aortic distensibility and compliance may participate in the genesis of cardiac hypertrophy in patients with hypertension. In these patients the increase in end-systolic stress, a determinant factor contributing to the development of cardiac hypertrophy, is influenced not only by the geometric properties of the ventricle but also by the level of systolic pressure. In patients with sustained essential hypertension, the degree of cardiac hypertrophy correlates significantly with the increase in aortic rigidity, which is assessed by the calculation of the characteristic impedance, by the measurement of carotid-femoral pulse-wave velocity, or by the calculation of the Peterson elastic modulus at the level of the aortic arch. Dihydralazine-like substances are unable to modify arterial stiffness, whereas calcium-entry blockers and converting-enzyme inhibitors improve arterial stiffness when achieving the same degree of blood pressure reduction. Modifications in the stiffness of the aorta and other large arteries must be considered to understand reversion of cardiac hypertrophy as a result of antihypertensive treatment.
主动脉扩张性和顺应性降低可能参与高血压患者心脏肥大的发生。在这些患者中,收缩末期应力增加是导致心脏肥大发展的一个决定性因素,它不仅受心室几何特性的影响,还受收缩压水平的影响。在持续性原发性高血压患者中,心脏肥大的程度与主动脉僵硬度的增加显著相关,主动脉僵硬度可通过计算特征阻抗、测量颈动脉-股动脉脉搏波速度或计算主动脉弓水平的彼得森弹性模量来评估。双肼屈嗪类物质无法改变动脉僵硬度,而钙通道阻滞剂和血管紧张素转换酶抑制剂在实现相同程度的血压降低时可改善动脉僵硬度。为了理解降压治疗导致心脏肥大逆转的情况,必须考虑主动脉和其他大动脉僵硬度的改变。